Dear [Recipient],

Re: Multiple Technology Appraisal (MTA) - Denosumab for the treatment of bone metastases from solid tumours (ID81) - Appraisal Consultation Document 2

I write on behalf of the NCRI/RCP/RCR/ACP/JCCO who collaborate to produce joint response to NICE oncological consultations. We are grateful for the opportunity to respond to the above ACD2 and wish to make the following comments.

The consensus from our experts in breast cancer (including patient advocates) is to welcome the NICE guidance in that area. Our experts in prostate cancer note that support is not recommended for patients in that area. Although they would wish to see all effective drugs available for patients, they feel it would have been inconsistent for NICE to have approved denosumab in prostate cancer. This is because NICE guidance has previously not approved zoledronic acid in this disease, and other NICE appraisals have rejected drugs that, unlike denosumab, improve survival in castrate-refractory disease.

Yours sincerely,

[Signature]

Registrar